Stock NVS NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novartis AG Nyse

Equities

NVS

US66987V1098

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 21:00:02 05/07/2024 BST 		5-day change 1st Jan Change
108.1 USD +1.26% Intraday chart for Novartis AG +1.57% +7.09%
07-05 Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code MT
07-05 UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 214,715 215,682 196,476 194,400 207,226 219,651 - -
Enterprise Value (EV) 1 230,615 240,182 204,667 203,434 219,237 233,043 231,316 225,314
P/E ratio 30.4 x 26.7 x 8.2 x 28.3 x 14.1 x 20.9 x 18.1 x 16.6 x
Yield 3.19% 3.56% 3.83% 3.87% 3.79% 3.4% 3.53% 3.75%
Capitalization / Revenue 4.53 x 4.43 x 3.81 x 3.85 x 4.56 x 4.46 x 4.28 x 4.22 x
EV / Revenue 4.86 x 4.94 x 3.96 x 4.02 x 4.82 x 4.73 x 4.5 x 4.33 x
EV / EBITDA 14.6 x 14.3 x 11.2 x 10.9 x 12.2 x 12 x 11.1 x 10.5 x
EV / FCF 17.9 x 20.5 x 15.4 x 17 x 16.6 x 16.7 x 14.9 x 13.8 x
FCF Yield 5.58% 4.87% 6.49% 5.87% 6.01% 5.99% 6.73% 7.27%
Price to Book 3.87 x 3.78 x 2.9 x 3.23 x 4.42 x 4.82 x 4.81 x 4.5 x
Nbr of stocks (in thousands) 2,264,608 2,274,506 2,237,092 2,150,980 2,055,460 2,040,406 - -
Reference price 2 94.81 94.83 87.83 90.38 100.8 107.7 107.7 107.7
Announcement Date 29/01/20 26/01/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 47,445 48,659 51,626 50,545 45,440 49,224 51,364 52,090
EBITDA 1 15,809 16,845 18,246 18,613 17,937 19,358 20,880 21,531
EBIT 1 14,112 15,416 16,588 16,665 16,372 18,265 19,414 19,934
Operating Margin 29.74% 31.68% 32.13% 32.97% 36.03% 37.11% 37.8% 38.27%
Earnings before Tax (EBT) 1 8,940 9,878 26,137 8,371 9,123 13,310 14,752 15,753
Net income 1 7,147 8,072 24,021 6,955 14,854 10,684 11,974 12,992
Net margin 15.06% 16.59% 46.53% 13.76% 32.69% 21.7% 23.31% 24.94%
EPS 2 3.120 3.550 10.71 3.190 7.150 5.150 5.962 6.483
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,967 15,560 16,372
FCF margin 27.14% 24.03% 25.73% 23.63% 29% 28.37% 30.29% 31.43%
FCF Conversion (EBITDA) 81.44% 69.4% 72.79% 64.18% 73.47% 72.15% 74.52% 76.04%
FCF Conversion (Net income) 180.15% 144.83% 55.29% 171.75% 88.72% 130.73% 129.95% 126.02%
Dividend per Share 2 3.025 3.375 3.360 3.500 3.823 3.657 3.795 4.032
Announcement Date 29/01/20 26/01/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 13,229 12,531 12,781 12,543 12,690 12,953 13,622 11,782 11,423 11,829 12,296 12,471 12,608 12,260 12,510
EBITDA 4,274 4,407 4,989 4,783 4,473 - 4,668 - 4,224 - - - - - -
EBIT 1 3,819 4,083 4,270 4,282 4,030 4,413 4,668 4,405 3,821 4,537 4,643 4,754 4,505 4,980 4,920
Operating Margin 28.87% 32.58% 33.41% 34.14% 31.76% 34.07% 34.27% 37.39% 33.45% 38.35% 37.76% 38.12% 35.73% 40.62% 39.33%
Earnings before Tax (EBT) 1 16,951 2,669 2,042 1,919 1,741 2,740 2,769 1,552 2,377 3,129 3,896 3,877 3,695 - -
Net income 1 16,308 2,222 1,695 1,575 1,466 2,293 2,316 1,513 8,480 2,688 2,820 2,826 2,481 - -
Net margin 123.27% 17.73% 13.26% 12.56% 11.55% 17.7% 17% 12.84% 74.24% 22.72% 22.93% 22.66% 19.68% - -
EPS 2 7.290 1.000 0.7700 0.7300 0.6900 1.090 1.110 0.7300 4.140 1.310 1.383 1.395 1.237 - -
Dividend per Share 2 3.360 - - - 3.500 - - - 3.823 - 0.9640 0.9669 0.9669 1.032 1.032
Announcement Date 02/02/22 26/04/22 19/07/22 25/10/22 01/02/23 25/04/23 18/07/23 24/10/23 31/01/24 23/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,900 24,500 8,191 9,034 12,011 13,392 11,664 5,663
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.006 x 1.454 x 0.4489 x 0.4854 x 0.6696 x 0.6918 x 0.5586 x 0.263 x
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,967 15,560 16,372
ROE (net income / shareholders' equity) 17.5% 23.5% 22.7% 21% 25.4% 32.5% 38.1% 38%
ROA (Net income/ Total Assets) 8.89% 6.45% 10.9% 10.7% 12.4% 10.5% 12.4% 14.4%
Assets 1 80,393 125,215 221,201 64,915 120,082 101,327 96,636 90,186
Book Value Per Share 2 24.50 25.10 30.30 28.00 22.80 22.30 22.40 23.90
Cash Flow per Share 2 5.880 5.950 6.670 6.480 6.910 7.790 8.460 8.750
Capex 1 2,257 1,275 1,378 1,198 1,060 1,196 1,273 1,328
Capex / Sales 4.76% 2.62% 2.67% 2.37% 2.33% 2.43% 2.48% 2.55%
Announcement Date 29/01/20 26/01/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107.7 USD
Average target price
111 USD
Spread / Average Target
+3.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
PFIZER, INC. Stock Pfizer, Inc.
-2.57% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. NVS Stock
  5. Financials Novartis AG